Program
vonoprazan
Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.
Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.
Drug pageVonoprazan: every studyMany companies study it; this page follows only the 48 they lead. All 100 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 310 open or running | phase 4since Feb 8, 2016 | Sep 16, 2011 | none ahead |
| Phathom Pharmaceuticals | 142 open or running | phase 3since Oct 10, 2019 | Oct 10, 2019 | Oct 20, 2027phase 3 · NCT07752407 |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 14, 2021 | Nov 14, 2021 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 1since Oct 14, 2024 | Oct 14, 2024 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Dec 9, 2025 | Dec 9, 2025 | none ahead |
Also a collaborator on its studies: Richmond Pharmacology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Phathom Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2019First study: phase 3 study in Erosive EsophagitisFirst studyNCT04124926 · 1,027 enrolled · United States, Bulgaria, Czechia and more
- Nov 15, 2019Phase 3 study in Helicobacter Pylori InfectionNCT04167670 · 1,046 enrolled · United States, Bulgaria, Czechia and more
- Sep 4, 20202 phase 1 studiesNCT04545944, NCT04558216
- Jan 19, 2021Phase 1 study in Healthy ParticipantsNCT04729101 · 44 enrolled · United States
- Mar 11, 2021Phase 2 study in HeartburnNCT04799158 · 458 enrolled · United States
- Jan 4, 2022Phase 3 study in HeartburnNCT05195528 · 776 enrolled · United States
- Apr 18, 2022Phase 1 study in Gastroesophageal RefluxNCT05343364 · 24 enrolled · United States
- May 4, 2022Phase 1 study in Gastroesophageal RefluxNCT05366738 · 27 enrolled · United States
- Oct 24, 2023Phase 1 study in Gastroesophageal RefluxNCT06106022 · 22 enrolled · United States
- Apr 25, 2024Phase 1 study in HeartburnNCT06391177 · 15 enrolled · United States
- Feb 14, 2025Phase 1 study in Healthy VolunteersNCT06831344 · 25 enrolled · United States
- Feb 24, 2025Phase 2 study in Eosinophilic EsophagitisNCT06851559 · 95 enrolled · United States
- Aug 3, 2026Phase 3 study in Gastroesophageal RefluxNCT07752407 · 500 planned · United States
Ahead
- Oct 20, 2027Primary completion: phase 3 study in Gastroesophageal RefluxNCT07752407
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 14 Phathom Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07752407Gastroesophageal Reflux · United States | 3 | Recruiting | Oct 20, 2027 | 500 |
| NCT06851559Eosinophilic Esophagitis · United States | 2 | Active, not recruiting | Sep 11, 2026 | 95 |
| NCT06831344Healthy Volunteers · United States | 1 | Completed | Apr 5, 2025 | 25 |
| NCT06391177Heartburn · United States | 1 | Completed | Sep 13, 2024 | 15 |
| NCT06106022Gastroesophageal Reflux · United States | 1 | Completed | Apr 16, 2024 | 22 |
| NCT05366738Gastroesophageal Reflux · United States | 1 | Completed | Jul 1, 2022 | 27 |
| NCT05343364Gastroesophageal Reflux · United States | 1 | Completed | May 30, 2023 | 24 |
| NCT05195528Heartburn · United States | 3 | Completed | Nov 21, 2022 | 776 |
| NCT04799158Heartburn · United States | 2 | Completed | Dec 16, 2021 | 458 |
| NCT04729101Healthy Participants · United States | 1 | Completed | Jun 12, 2021 | 44 |
| NCT04558216Healthy Participants · United States | 1 | Withdrawn | Feb 7, 2021 | 0 |
| NCT04545944Healthy Volunteers · United States | 1 | Completed | Nov 13, 2020 | 20 |
| NCT04167670Helicobacter Pylori Infection · United States, Bulgaria, Czechia and more | 3 | Completed | Mar 10, 2021 | 1,046 |
| NCT04124926Erosive Esophagitis · United States, Bulgaria, Czechia and more | 3 | Completed | Jul 29, 2021 | 1,027 |
How it is read
Names in the registry
- “TAK-438”, 32 entries
- “Vonoprazan”, 20 entries
- “Vonoprazan (Reference)”, 1 entry
- “Vonoprazan Tablets”, 1 entry
- “VOQUEZNA® Tablets”, 1 entry
Conditions, from the studies’ own filings
- Esophagitis, 9 studies
- Stomach Ulcer, 9 studies
- Gastroesophageal Reflux, 7 studies
- Heartburn, 3 studies
- Duodenal Ulcer, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.